Pharmaceuticals, Biotechnology and Life Sciences
The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection
Reblozyl regulates late-stage red blood cell (RBC) maturation to potentially reduce or eliminate the need for regular RBC transfusions Reblozyl…
UbiVac has announced working with BMS on Phase Ib study to combine UbiVac’s DRibble® Platform Vaccine, DPV-001 with anti-OX40 (BMS-986178) and Opdivo (nivolumab) to test hypothesis that this combination will augment anticancer immunity in advanced triple negative breast cancer.
Zeposia offers relapsing remitting multiple sclerosis (RRMS) patients with active disease in the European Union a new oral option to…
Bristol Myers Squib has presented a wide range of research platforms across immunotherapy, cell therapy and protein degradation underscore commitment to advancing cancer research and treatments.
Bristol Myers Squibb has reported first quarter revenues of $10.8 Billion, an increase of 82%, on a pro forma basis, revenue increase of 13% or 8% excluding impact of COVID-19.
U.S. FDA set target action date of September 3, 2020 Application based on results from the Phase 3 QUAZAR®-AML-001 study…
Oxford Biomedica has signed a new Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s company, Juno Therapeutics to use Oxford Biomedica’s LentiVector platform for its application in CAR-T and TCR-T programmes in oncology and other indications.
Bristol/Myers Squibb said Wednesday it has submitted a Biologics License Applications (BLA) to the FDA, which includes data from Transcend NHL 001 trial, evaluating liso-cel in patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma.
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to…